Pfiz­er ax­es 6 ear­ly to late-stage can­cer stud­ies from the pipeline — with one oth­er cut for sick­le cell dis­ease

Pfiz­er trimmed a group of 3 R&D pro­grams us­ing their PD-L1 Baven­cio — part­nered with Mer­ck KGaA — in their lat­est pipeline cull.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.